Paul Brennan

Paul Brennan is a Grit DAily contributor and president/CEO of NervGen Pharma Corp., a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases. He can be reached at pb[email protected]

More articles by Paul Brennan

Paul Brennan
on June 16, 2022

Alzheimer’s Breakthrough: A Disruptive Systemic Approach Is Poised To Demonstrate Value

Paul Brennan
on April 2, 2022

Neuroscientists Are Confident the Secret to Reversing Brain Damage Is Restoring Brain Plasticity

Paul Brennan
on April 7, 2021

High Drug Prices in the US Underwrite the Lion’s Share of Global Pharma Profits and Research

Paul Brennan
on January 7, 2021

The Acceleration of Alzheimer’s Disease Drug Innovations

Paul Brennan
on December 23, 2020

Therapeutics Innovation in the Era of a Pandemic

Paul Brennan
on November 17, 2020

Defining a Successful Biotech Entrepreneur